Martin Landray
#86,809
Most Influential Person Now
Researcher
Martin Landray's AcademicInfluence.com Rankings
Martin Landraylaw Degrees
Law
#2855
World Rank
#3558
Historical Rank
Common Law
#171
World Rank
#184
Historical Rank
International Law
#952
World Rank
#1153
Historical Rank
Download Badge
Law
Martin Landray's Degrees
- Bachelors Biochemistry University of Oxford
- PhD Clinical Medicine University of Oxford
Why Is Martin Landray Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sir Martin Jonathan Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals. Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.
Martin Landray's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age (2015) (5094)
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report (2020) (4350)
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (2011) (2093)
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. (2020) (1694)
- Effects of extended-release niacin with laropiprant in high-risk patients. (2014) (1242)
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (1083)
- Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19 (2020) (1040)
- Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. (2011) (645)
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013) (605)
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013) (605)
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2020) (516)
- COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England (2020) (464)
- Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. (2005) (427)
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. (2021) (391)
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
- Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial (2021) (351)
- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (316)
- Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. (2004) (302)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. (2018) (285)
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial (2021) (282)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (2018) (248)
- The Magic of Randomization versus the Myth of Real-World Evidence. (2020) (235)
- Abnormalities of endothelial function in patients with predialysis renal failure (2000) (235)
- Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. (2016) (207)
- Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (201)
- First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. (2005) (189)
- The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study (2018) (184)
- Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study (2017) (182)
- Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (162)
- Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study (2010) (160)
- Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study (2021) (160)
- Effects of lowering LDL cholesterol on progression of kidney disease. (2014) (140)
- Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial (2014) (129)
- Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (116)
- Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. (2018) (116)
- Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. (2001) (111)
- The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. (2006) (108)
- Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? (2000) (106)
- An overview of antithrombotic therapy (2002) (105)
- Analyses of cancer data from three ezetimibe trials. (2008) (100)
- Randomized clinical trials--removing unnecessary obstacles. (2013) (97)
- Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference (2017) (94)
- Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial (2018) (94)
- Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial (2018) (94)
- Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study (2000) (91)
- A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. (2001) (87)
- Empagliflozin in Patients with Chronic Kidney Disease (2022) (86)
- Neprilysin inhibition in chronic kidney disease (2014) (83)
- Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (2022) (80)
- Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. (2003) (79)
- Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis (2011) (77)
- Lipid-lowering drugs and homocysteine (1999) (76)
- What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? (2015) (73)
- Trends in the Incidence and Recurrence of Inpatient-Treated Spontaneous Pneumothorax, 1968-2016 (2018) (70)
- Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. (2016) (65)
- Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP) (2014) (63)
- Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP) (2016) (60)
- Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP) (2016) (60)
- Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review (2018) (60)
- Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study (2018) (55)
- Homocysteine, renal function, and risk of cardiovascular disease. (2003) (50)
- Evidence for the Prevention and Treatment of Stroke in Dialysis Patients (2014) (49)
- Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. (1998) (45)
- Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial [accepted manuscript] (2018) (43)
- Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials (2014) (42)
- Enhancing clinical evidence by proactively building quality into clinical trials (2016) (41)
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
- Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. (2019) (37)
- Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony. (2020) (36)
- Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD (2016) (34)
- Serum free light chains and the risk of ESRD and death in CKD. (2011) (33)
- Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). (2017) (33)
- Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study (2019) (32)
- Potential health and economic impacts of dexamethasone treatment for patients with COVID-19 (2021) (32)
- Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease (2017) (30)
- Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation (2017) (29)
- Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients (2007) (29)
- Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation (2017) (29)
- A Practical Method of Measuring Glomerular Filtration Rate by Iohexol Clearance Using Dried Capillary Blood Spots (2007) (27)
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial (2022) (27)
- Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials (2020) (27)
- Impact of ADCY9 Genotype on Response to Anacetrapib (2019) (27)
- Making trials part of good clinical care: lessons from the RECOVERY trial (2021) (25)
- Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (2016) (24)
- Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (2016) (24)
- Which cardiovascular risk factors matter in chronic kidney disease? (2006) (24)
- CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials (2007) (24)
- Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men (2010) (24)
- Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom (2020) (23)
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
- Effect of amiodarone on mortality (1998) (22)
- Testing the practical aspects of therapeutics by objective structured clinical examination (2004) (22)
- Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials (2004) (22)
- Biliary Tract and Liver Complications in Polycystic Kidney Disease. (2017) (22)
- Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol (2013) (22)
- Risk-adapted approaches to the management of clinical trials: guidance from the Department of Health (DH)/Medical Research Council(MRC)/Medicines and Healthcare Products Regulatory Agency (MHRA) Clinical Trials Working Group (2011) (21)
- Impact of CKD on Household Income (2017) (20)
- Impact of CKD on Household Income (2017) (20)
- The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. (2014) (19)
- Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy (2018) (19)
- White coat hypertension and carotid atherosclerosis. (1999) (19)
- Clinical Trials: Rethinking How We Ensure Quality (2012) (19)
- Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial (2018) (18)
- Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. (2016) (18)
- A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease (2017) (17)
- Improving public health by improving clinical trial guidelines and their application (2017) (17)
- Niacin for reduction of cardiovascular risk. (2014) (17)
- Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension. (2002) (17)
- Lopinavir-ritonavir in Hospitalised Patients with COVID-19 – a randomised, controlled, open-label, platform trial (2020) (16)
- Conventional and Genetic Evidence on the Association between Adiposity and CKD. (2020) (16)
- Underuse of statins in patients with atherosclerotic ischemic stroke in China. (2012) (15)
- Effect of Atorvastatin on Low-Density Lipoprotein Subfraction Profile (1999) (15)
- Pyrexia, anaemia and acute renal failure secondary to omeprazole. (1998) (15)
- Early identification and management of chronic kidney disease : summary of NICE guidance. Commentary (2008) (14)
- Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients. (2012) (14)
- Increasing the use of mobile technology–derived endpoints in clinical trials (2018) (14)
- Lipids in chronic kidney disease. (2010) (13)
- Randomized clinical trials--removing obstacles. (2013) (13)
- Challenges of linking to routine healthcare records in UK Biobank (2015) (12)
- Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2020) (11)
- Cardiovascular aspects of chronic kidney disease (2011) (11)
- Evaluating treatment effects reliably (2002) (11)
- Serious Adverse Effects of Extended-Release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. (2019) (10)
- Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection (2017) (10)
- A decade of the Clinical Trials Transformation Initiative: What have we accomplished? What have we learned? (2018) (10)
- Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (2017) (10)
- Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes (2019) (10)
- The Association of Serum Free Light Chains With Mortality and Progression to End‐Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta‐analysis (2017) (10)
- Dual blockade of the renin-angiotensin system: are two better than one? (2009) (8)
- Two-year survival among patients with chronic-kidney disease not on dialysis: The chronic renal impairment in Birmingham (CRIB) study. (2003) (8)
- Potential health and economic impacts of dexamethasone treatment for patients with COVID-19 (2020) (8)
- Realising the full potential of data-enabled trials in the UK: a call for action (2021) (8)
- Developing novel endpoints, generated using mobile technology, for use in clinical trials: a clinical trials transformation initiative (CTTI) project (2017) (8)
- Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease (2021) (7)
- Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease (2019) (6)
- Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank (2020) (6)
- Accelerometer-measured physical activity and functional behaviours among people on dialysis (2020) (6)
- Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease (2019) (6)
- Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. (2000) (5)
- Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs (2016) (5)
- Commentary: Controversies in NICE guidance on chronic kidney disease (2008) (5)
- Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic? (2020) (5)
- Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442-1451. (2018) (5)
- Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK (2021) (5)
- Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments (2021) (4)
- Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply (2021) (4)
- Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial (2022) (4)
- Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices) (2021) (4)
- Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial (2022) (4)
- Renal function: an emerging risk factor for cardiovascular disease? (2001) (4)
- Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply. (2021) (3)
- Central statistical monitoring in multicentre clinical trials: developing statistical approaches for analysing key risk indicators (2013) (2)
- Impact of renal function on the effects of reducing LDL cholesterol with statin-based regimens: meta-analysis of individual data from 28 randomised trials. (2016) (2)
- Facilitating participation in clinical trials during pregnancy (2023) (2)
- Data provenance and integrity of health-care systems data for clinical trials (2022) (2)
- Investigating modifications to participant information materials to improve recruitment into a large randomized trial (2019) (2)
- Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. (2000) (2)
- Improving efficiency of on-site monitoring in multicentre clinical trials by targeting visits (2015) (2)
- Investigating modifications to participant information materials to improve recruitment into a large randomized trial (2019) (2)
- [ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study]. (2013) (2)
- Survey of statin usage in 4429 diabetic patients with atherosclerostic cardiovascular disease in China (2010) (2)
- Benefits of lowering cholesterol in chronic kidney disease – Authors' reply (2011) (2)
- Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths (2015) (2)
- Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2023) (1)
- Cross-sectional study of statin use among high-risk patients with coronary heart disease in China (2010) (1)
- Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes (2009) (1)
- How was it for you? - obtaining feedback from staff at study sites for the HPS2-thrive trial (2015) (1)
- Survey of treatment of hypertension among patients with ischemic stroke (2011) (1)
- Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637 (2018) (1)
- Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2022) (1)
- Dark necrotic mucosa in sinonasal mucormycosis (2016) (1)
- Ethics and international research (multiple letters) [2] (1998) (1)
- A Pragmatic Randomized Feasibility Trial of Influenza Vaccines (2023) (1)
- Observational Cacophony, Randomized Harmony: Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments (2020) (1)
- Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology (2022) (1)
- Sudden death: ACE inhibitors and beta-blockers (2000) (1)
- Low Use of Statins among High-risk Patients in China (2010) (1)
- Abstract 23077: The Effects Of Prolonged Anacetrapib Therapy On First And Subsequent Occlusive Vascular Events (2017) (0)
- Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2022) (0)
- Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. (2015) (0)
- Adverse effects of drugs on the development of ischaemic heart disease (2000) (0)
- CONVENTIONAL AND GENETIC EVIDENCE ON THE ASSOCIATION BETWEEN ADIPOSITY AND CHRONIC KIDNEY DISEASE (2020) (0)
- Haynes, R. et al. (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial (2018) (0)
- Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors (2022) (0)
- Why use cdisc for trials not submitted to regulators? Lessons from the experience of an academic clinical trial unit (2017) (0)
- Results of a Large Randomized Controlled Trial of Alemtuzumab‐Versus Basiliximab‐Based Induction Therapy in Kidney Transplantation.: Abstract# A2986 (2014) (0)
- Alemtuzumab induction therapy in kidney transplantation – Authors' reply (2015) (0)
- Allocated but not treated: the silent 16% – Authors' reply (2022) (0)
- White coat hypertension and carotid atheroscierosis: is there a relationship? (1998) (0)
- Using OWL to classify adverse events (2017) (0)
- Detecting cognitive effects of vascular event prevention in randomized trials (2019) (0)
- ELECTIVE CONVERSION TO SIROLIMUS VS. CONTINUED TACROLIMUS IN KIDNEY TRANSPLANTATION (THE 3C STUDY): RESULTS OF A RANDOMIZED TRIAL (2018) (0)
- G001: Malignant phase hypertension is associated with abnormalities of low density lipoprotein subfraction profiles (2000) (0)
- Using dedicated study laptops to enhance data quality, participant safety, and trial efficiency: experience from a large-scale, international, randomized clinical trial (2017) (0)
- Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, SEARCH and HPS2-THRIVE studies (2015) (0)
- Author Correction: Potential health and economic impacts of dexamethasone treatment for patients with COVID-19 (2021) (0)
- Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial. (2022) (0)
- MSR45 Challenges in Extrapolation When There Are Multiple Health Outcomes (2022) (0)
- Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial (2011) (0)
- The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study (2018) (0)
- Impact of adverse events on quality of life and hospital costs in secondary cardiovascular disease prevention (2021) (0)
- ELEVATED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) AND SYMMETRIC DIMETHYLARGININE (SDMA) CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS (2005) (0)
- Randomization versus Real-World Evidence. Reply. (2020) (0)
- Preventive cardiology abstractA randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease☆ (2001) (0)
- Clinical trials: how to get closer to the right answer with less effort. (2013) (0)
- Increased MGUS prevelance in chronic kidney disease patients (2007) (0)
- Coronary Artery Disease A Randomized Double-Blind Placebo-Controlled Trial of the Effect of Homocysteine-Lowering Therapy With Folic Acid on Endothelial Function in Patients With Coronary Artery Disease (2016) (0)
- Methodology for UK recruitment into a large-scale international clinical trial (2015) (0)
- Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2023) (0)
- Impact of prior myocardial infarction and vascular disease on the risk of subsequent cardiac events among 68 730 patients commencing dialysis. (2002) (0)
- Factors influencing recruitment in large randomised trials (2017) (0)
- Investigating possible fraudulent activity at a research site (2015) (0)
- Association of Atherogenic Low Density Lipoprotein (Ldl) Subfractions with Carotid Atherosclerosis (1998) (0)
- ELEVATED LEVELS OF N-TERMINAL BRAIN NATRIURETIC PEPTIDE AND TROPONIN T CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS (2005) (0)
- Chronic kidney disease patients and renal transplant recipients rave an increased incidence of monoclonal gammopathies. (2007) (0)
- Impact of the COVID-19 pandemic on admission rates for, and management of, acute coronary syndromes in England. (2020) (0)
- Ethics and international research. Potential enticement of placebo trials needs to be debated. (1998) (0)
- Producing CDISC compliant data and metadata for regulatory submissions (2017) (0)
- Fast tracking informative clinical trials: lessons for mental health (2023) (0)
- Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study (2019) (0)
- Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease (2019) (0)
- Quality by design: using intelligent forms to ensure study protocol compliance and participant safety (2015) (0)
- SERUM LIPIDS DO NOT PREDICT CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS (2005) (0)
- Chronic kidney disease patients and renal transplant recipients have a high prevalent rate of MGUS (2007) (0)
- Improving the Quality of Carotid Endarterectomy and Carotid Artery Stenting: Identifying Hospital-Level Structural Factors that Affect Outcomes in the Prevention of Thromboembolic Strokes (2019) (0)
- IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE (2015) (0)
This paper list is powered by the following services:
Other Resources About Martin Landray
What Schools Are Affiliated With Martin Landray?
Martin Landray is affiliated with the following schools:
